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Abstract
Purpose: Definitive radiotherapy is often used for chest wall desmoid tumours due to size or anatomical location.
The delivery of radiotherapy is challenging due to the large size and constraints of normal surrounding structures.
We compared the dosimetry of 3D conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT) and
volumetric-modulated arc radiotherapy (VMAT) to evaluate the best treatment option.
Methods and materials: Ten consecutive patients with inoperable chest wall desmoid tumours (PTV range
416–4549 cm3) were selected. For each patient, 3DCRT, IMRT and VMAT plans were generated and the Conformity
Index (CI), organ at risk (OAR) doses and monitor unit (MU) were evaluated. The Wilcoxon signed-rank test was
used to compare dose delivered to both target and OARs.
Results: The mean number of fields for 3DCRT and IMRT were 6.3 ± 2.1, 7.2 ± 1.8. The mean number of arcs for
VMAT was 3.7 ± 1.1. The mean conformity index of VMAT (0.98 ± 0.14) was similar to that of IMRT (1.03 ± 0.13),
both of which were significantly better than 3DCRT (1.35 ± 0.20; p = 0.005).
The mean dose to lung was significantly higher for 3DCRT (11.9Gy ± 7.9) compared to IMRT (9.4Gy ± 5.4, p = 0.014)
and VMAT (8.9Gy ± 4.5, p = 0.017). For the 3 females, the low dose regions in the ipsilateral breast for VMAT were
generally less with VMAT. IMRT plans required 1427 ± 532 MU per fraction which was almost 4-fold higher than
3DCRT (313 ± 112, P = 0.005). Compared to IMRT, VMAT plans required 60 % less MU (570 ± 285, P = 0.005).
Conclusions: For inoperable chest wall desmoid tumours, VMAT delivered equivalent target coverage when
compared to IMRT but required 60 % less MU. Both VMAT and IMRT were superior to 3DCRT in terms of better PTV
coverage and sparing of lung tissue.
Introduction
Desmoid-type fibromatosis is a locally aggressive, non-
metastasizing mesenchymal tumour characterised by
clonal proliferation of myofibroblasts [1]. Although rare,
it is a highly heterogenous disease that has unpredictable
behaviour and can arise almost anywhere in the body
[2]. Subtypes based upon anatomical location include
intra-abdominal fibromatosis, abdominal wall fibromatosis,
and extra-abdominal fibromatosis [3]. Extra-abdominal
fibromatoses mainly affect individuals between puberty and
forty years of age and arise in a variety of anatomic
locations, including the shoulder, chest wall, back and thigh
[1]. Traditionally, wide surgical excision was considered to
be the standard of care. However, due to their pattern of
infiltrative and nonencapsulated growth, surgery can be
associated with considerable functional and cosmetic
morbidity, and high local recurrences rates [4–6]. Conse-
quently, an upfront wait and see approach has been
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favoured in recent years, with treatment mandated in the
case of disease progression [2].
Definitive radiotherapy (RT) plays an important role in
the treatment of desmoid tumours that are inoperable due
to size or anatomical location. In a comparative retrospect-
ive review, definitive RT in a total of 102 patients treated
with a dose between 50 and 60 Gy resulted in local control
rates of 78 % (80/102), significantly higher than that for sur-
gery alone (61 %; P = 0.022) and no different when com-
pared with surgery and adjuvant RT (75 %) [7]. However,
the delivery of RT can be challenging due to the large size
of some desmoid tumours and constraints of normal sur-
rounding tissues. For example, chest wall desmoid tumours
lie close to key organs including heart, lung and brachial
plexus. As published RT series for the treatment of desmoid
tumours have small patient numbers often spread over
many years there has been wide variation in the reported
RT dose, fractionation and technique, making it difficult to
ascertain evidence-based data on optimal RT techniques.
Furthermore, no study has previously compared RT plan-
ning techniques to optimize dose to inoperable desmoid tu-
mours while minimising dose to major adjacent organs at
risk.
We compared the performance of 3D conformal
radiotherapy (3DCRT), intensity-modulated radiother-
apy (IMRT) and volumetric-modulated arc radiotherapy
(VMAT) to evaluate the best treatment technique for
inoperable large volume chest wall desmoid tumour.
Materials and methods
The study group comprised of 10 consecutive patients
with inoperable chest wall desmoid tumours diagnosed
between 2009 and 2013. All patients were assessed in a
multidisciplinary clinic prior to undergoing RT. The
study was approved by the ethics committee. For each
patient, optimised 3DCRT, IMRT and VMAT plans were
generated to a prescribed dose of 56Gy in 28 fractions
based upon previously reported recommendations [8, 9].
The first three patients (patients 1–3) were planned
using 3DCRT, IMRT and VMAT, prior to the decision to
proceed with VMAT for treatment. The remainder of
the patients had VMAT plans generated for their treat-
ment with 3D and IMRT plans generated retrospectively
for the purpose of this study.
The Gross Tumour Volume (GTV) was defined based
upon each patient’s MRI. The Clinical Target Volume
(CTV) was defined by expanding the GTV by 4–5 cm
unless the area was bound by another anatomical struc-
ture. The Planning Target Volume (PTV) was defined as
the CTV + 0.5 cm. An online strategy was employed for
acquisition of images and their verification and correc-
tion prior to treatment. Organs at risk (OAR) considered
in the treatment plan included heart, lung and breasts
(in female patients).
A comparison of the Homogeneity Index (defined as
difference between the dose covering 5 % and dose cover-
ing 95 % of the PTV), Conformity Index (defined as the
ratio between the volume receiving at least 95 % of the
prescribed dose and the PTV), OAR doses, monitor units
(MUs) and treatment delivery time was evaluated. The
Wilcoxon signed-rank test was used to compare dose
delivered to both target and OARs. Statistical analyses
were performed in SPSS (Version 22).
Results
Table 1 summarises the baseline demographics of the
ten patients in the study. The age range was 20 to 64.
Three subjects were female and seven were male. Three
tumours were right sided and seven were left sided. All
tumours were large; a feature which made surgery a less
desirable treatment modality, with the PTV volume
ranging from 416 to 4539 cm3.
The mean number of fields (± standard deviation) for
3DCRT and IMRT were 6.3 ± 2.1 and 7.2 ± 1.8 respect-
ively. The mean number of arcs for VMAT was 3.7 ± 1.1.
Table 2 summarises the dosimetric results for the PTV.
The minimum dose to the PTV was significantly higher
for 3DCRT compared to IMRT and VMAT plans, while
there was no difference in the maximum or mean dose
to PTV. Due to significant inter-individual variability in
the homogeneity index within each plan type (particu-
larly for VMAT), the overall homogeneity index was
statistically similar for the three plan types. The mean
Table 1 Baseline demographics of subjects
Patient
Number





1 29 F L anterior
chest wall
6.5 × 3.6 × 2.1 534
2 47 M R posterior
chest wall
10.0 × 3.5 × 5.5 2082
3 64 M R anterior
chest wall
6.9 × 2.6 × 3.0 767
4 34 F L axilla 7.6 × 11.8 × 11.5 1017
5 34 M L axilla and
lateral chest wall
10.5 × 12.5 × 5.0 3896
6 22 M R axilla and
supraclavicular fossa
10.3 × 5.9 × 5.2 1303
7 46 M R anteriolateral
chest wall
15.0 × 20.0 × 6.0 4539
8 49 M L anterior
chest wall
8.5 × 5.6 × 6.8 950
9 41 F L anterior
chest wall
4.3 × 1.4 × 2.5 416
10 20 M L neck and
supraclavicular fossa
8.7 × 5.5 × 6.7 646
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conformity index of VMAT (0.98 ± 0.14) was similar to
that of IMRT (1.03 ± 0.13), both of which were signifi-
cantly better than 3DCRT (1.35 ± 0.20; p = 0.005).
IMRT plans required 1427 ± 532 MU per fraction
which was almost 4-fold higher than 3DCRT (313 ± 112,
P = 0.005). Compared to IMRT, VMAT plans required
60 % less MU on the machine (570 ± 285, P = 0.005).
The mean beam on time was 206 ± 122 s for 3DCRT,
which was significantly lower than that of VMAT (366 ±
164 s, P = 0.005) and marginally lower than that of
IMRT (302 ± 86 s, P = 0.056).
Table 3 and Fig. 1 summarise the dosimetric results for
organs at risk. The mean dose to heart was statistically
similar for all three plan types. However, the mean dose to
lung was significantly higher for 3DCRT (11.9Gy ± 7.9)
compared to IMRT (9.4Gy ± 5.4, p = 0.014) and VMAT
(8.9Gy ± 4.5, p = 0.017). There were no significant differ-
ences in the dose to lung for the IMRT plans compared to
VMAT plans (p = 0.386). Similarly, the V20 was signifi-
cantly higher for 3DCRT (21.0Gy ± 18.7) compared with
IMRT (16.2Gy ± 12.4, p = 0.021) and VMAT (12.1 ± 7.5Gy,
p = 0.028). For the 3 female patients, the low dose regions
in the ipsilateral breast for VMAT were generally less than
IMRT and 3DCRT. As shown in Fig. 1, the volume of lung
and left (ipsilateral) breast irradiated at low and medium
doses was lower for IMRT and VMAT compared to
3DCRT. The DVH for heart and the right (contralateral)
breast were very similar. A typical plan for a female pa-
tient with a large left sided anterior chest wall desmoid
tumour is shown in Fig. 2, illustrating the improved OAR
sparing achieved with VMAT and IMRT compared to
3DCRT.
Table 2 Summary of dosimetric results for PTV
Parameter 3DCRT IMRT VMAT P value
3DCRT vs IMRT 3DCRT vs VMAT IMRT vs VMAT
Minimum (Gy) 40.0 ± 8.8 32.5 ± 11.2 30.57 ± 13.5 0.028 0.037 0.508
Maximum (Gy) 63.8 ± 3.0 67.5 ± 8.9 63.9 ± 2.9 0.203 0.959 0.333
Mean (Gy) 58.2 ± 1.9 57.5 ± 2.0 57.1 ± 1.4 0.092 0.074 0.878
D5%(Gy) 61.6 ± 2.2 60.5 ± 3.0 60.3 ± 2.5 0.169 0.037 0.859
D95%(Gy) 55.3 ± 2.8 53.3 ± 2.8 50.0 ± 8.6 0.203 0.053 0.114
HI (D5 % -D95 % ; Gy) 6.27 ± 2.76 7.20 ± 4.60 10.25 ± 10.42 0.575 0.386 0.139
V95 % (%) 95.5 ± 3.2 92.2 ± 7.2 92.5 ± 5.6 0.333 0.139 0.799
CI 1.35 ± 0.2 1.03 ± 0.13 0.98 ± 0.14 0.005 0.005 0.445
MU 313 ± 112 1427 ± 532 570 ± 285 0.005 0.432 0.005
Beam on time (second) 206 ± 122 302 ± 86 366 ± 164 0.056 0.005 0.231
CI Conformity index, defined as the ratio between the volume receiving at least 95 % of the prescribed dose and the volume of the PTV, HI Homogeneity index,
defined as difference between the dose covering 5 % and dose covering 95 % of the PTV. P value determined using Wilcoxon matched pair rank sum test in SPSS
Table 3 Summary of dosimetric results for Organs At Risk
Parameter Patients Parameter 3DCRT IMRT VMAT P value
3DCRT vs IMRT 3DCRT vs VMAT IMRT vs VMAT
Heart 10/10 Mean (Gy) 8.3 ± 7.6 5.7 ± 3.7 6.5 ± 4.3 0.074 0.333 0.093
V25Gy (%) 8.1 ± 14.3 3.6 ± 4.0 3.9 ± 4.9 0.310 0.735 0.917
V30Gy (%) 5.6 ± 10.0 3.9 ± 5.4 2.3 ± 3.5 0.237 0.735 0.753
Lung 10/10 Mean (Gy) 11.9 ± 7.9 9.4 ± 5.4 8.9 ± 4.5 0.014 0.017 0.386
V20Gy (%) 21.0 ± 18.7 16.2 ± 12.4 12.1 ± 7.5 0.021 0.028 0.515
Right breast (contralateral breast) 3/10 Mean (Gy) 3.3 ± 0.5 2.7 ± 0.5 3.5 ± 1.6 0.285 0.593 0.285
V10Gy (%) 2.6 ± 3.0 2.7 ± 2.4 5.2 ± 7.7 1.000 1.000 0.655
V20Gy (%) 1.4 ± 2.1 0.5 ± 0.8 0.4 ± 0.7 0.180 0.655 0.655
Left breast (ipsilateral breast) 3/10 Mean (Gy) 19.7 ± 12.7 11.4 ± 6.8 11.1 ± 7.6 0.109 0.109 0.593
V10Gy (%) 44.4 ± 36.2 38.9 ± 31.6 28.8 ± 20.4 0.180 0.285 0.593
V20Gy (%) 28.9 ± 20.0 18.2 ± 13.6 15.7 ± 18.4 0.285 0.593 0.593
Mean (Gy) refers to the mean dose to organ at risk. V25Gy (%) refers to the percentage of the volume receiving 25 Gy dose. P value determined using Wilcoxon
matched pair rank sum test in SPSS
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Discussion
This is the first comparative planning study on the
performance of 3DCRT, IMRT and VMAT plans for
patients with unresectable chest wall desmoid tumours
undergoing definitive RT. Our findings are consistent
with a large body of literature demonstrating that
VMAT achieves highly conformal dose distribution with
better target volume coverage and sparing of normal tis-
sues compared with conventional techniques (reviewed
in [10]). In particular, PTV coverage was found to be
similar for IMRT and VMAT, with both techniques hav-
ing superior conformity index compared to 3DCRT.
Similar findings have been reported in planning studies
Fig. 1 Mean Dose Volume Histograms for OAR
Fig. 2 Example of dose distributions for example case for VMAT (A), IMRT (B) and 3DCRT (C)
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of other tumour sites including prostate [11], anal [12]
head and neck [13] and CNS tumours [14].
Definitive RT is emerging as an important treatment mo-
dality for desmoid tumours. A multicentre phase II study of
primary RT for inoperable desmoid tumours showed mod-
erate dose RT as an effective treatment option with absence
of local progression in 81.5 % of subjects at 3 years [9].
However due to the size and difficult location of chest wall
desmoid tumours, recurrence and RT treatment sequelae
can considerably impair functional outcomes and quality of
life. In the current study, a dose of 56 Gy in 28 fractions
was chosen based upon existing literature showing radi-
ation doses over 56 Gy did not significantly improve local
control but were associated with increased risk of complica-
tions [8].
We showed that VMAT required 60 % less MUs on
the machine compared to IMRT in this study. The lower
MUs is also associated with less interleaf scatter dose
and reduced radiotherapy dose to normal tissues, thus
minimising the risk of second radiation-induced malig-
nancies [15] which is of particular relevance when deliv-
ering radiotherapy to young patients with desmoid
tumours (age range 20–64 in our study). VMAT was
found to have similar beam on time compared to IMRT
and both required more beam on time compared to
3DCRT. However, the large number of fixed gantry field
with IMRT approach increases the total treatment time
compared with VMAT and this is likely to impact on
intrafractional patient movement and clinical through-
put of the radiotherapy department.
As expected, this study found that dose to the lung and
ipsilateral breast was also substantially lower for IMRT
and VMAT compared to 3DCRT (Fig. 2). Additionally
VMAT had a trend towards lower ipsilateral breast dose
compared to IMRT, although the small numbers of female
patients in our study precluded an ability to assess statis-
tical significance of this finding. Nevertheless, reduced
OAR dose is important to minimise late effects given that
desmoid tumour is a benign condition primarily affecting
young patients. There have been varying reports on OAR
sparing for IMRT versus VMAT in the literature. In pros-
tate cancer planning studies VMAT has been shown in
most studies to have better sparing of rectum, bladder and
urethra compared to IMRT, whereas OAR sparing was
similar or only slightly better for VMAT compared to
IMRT in head and neck cancers [10]. In breast cancer
planning studies in a similar anatomical area to desmoid
tumour plans, VMAT has shown to be better than IMRT
and 3DCRT for sparing of heart and ipsilateral lung as
well as the contralateral breast [16, 17]. Future studies
should compare IMRT and VMAT in a larger number of
female patients to clarify whether VMAT is associated
with improved sparing of the ipsilateral breast, given the
risk of secondary malignancies in young women.
Conclusion
In summary, this is the first comprehensive planning study
to evaluate VMAT, IMRT and 3DCRT planning techniques
for unresectable chest wall desmoid tumours. Our findings
show that both VMAT and IMRT provided superior PTV
coverage and improved OAR sparing compared to 3DCRT.
VMAT was associated with reduced MUs with a trend
towards lower ipsilateral breast dose compared to IMRT.
Further prospective studies are required to assess whether
VMAT would translate to clinical benefits especially re-
duced incidence of late effects compared to IMRT, however
this is challenging due to the low incidence of desmoid
tumour and the long follow-up that would be required.
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